Tuesday, September 30, 2014 9:27:55 AM
Endometriosis, one of the most common gynecological disorders that is estimated to affect approximately one in ten women in their reproductive (child-bearing) years and is the number one cause of infertility.
Management believes this pharmaceutical product that is being developed and commercialized using FDA approved novel compounds will stop the progression of the diseases with minimal adverse side effects. There are an estimated 27.5 million symptomatic women in the US and additional over 100 million worldwide who suffer from endometriosis. In the US, only an estimated 2.5 million have been diagnosed and are being treated for endometriosis.
This pharmaceutical application was developed to halt development and progression of the often painful, debilitating, and aging symptoms of endometriosis in women. The only way to diagnose endometriosis today is an invasive laparoscopy that requires general anesthesia with a cost of $8,000 to $20,000. Over 50% of the time endometriosis is NOT found as a result of the limits associated with diagnostic laparoscopy.
This novel pharmaceutical compound completely suppresses endometriosis in women before and after the on-set of the disease.
For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, #757-306-6090, www.gbhd.net
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM